These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6530355)

  • 21. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia.
    Nanda S; Moore H; Lenhart S
    Math Biosci; 2007 Nov; 210(1):143-56. PubMed ID: 17599363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repopulation of cancer cells during therapy: an important cause of treatment failure.
    Kim JJ; Tannock IF
    Nat Rev Cancer; 2005 Jul; 5(7):516-25. PubMed ID: 15965493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy followed by syngeneic dendritic cell injection in the mouse: findings and implications for human treatment.
    Cavanagh WA; Tjoa BA; Ragde H
    Urology; 2007 Dec; 70(6 Suppl):36-41. PubMed ID: 18194710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune surveillance and anti-tumor immune responses: an anatomical perspective.
    Zimmermann VS; Benigni F; Mondino A
    Immunol Lett; 2005 Apr; 98(1):1-8. PubMed ID: 15790503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective cytotoxic activity of a novel ribonucleoside diphosphate reductase inhibitor MDL-101,731 against thyroid cancer in vitro.
    Kotchetkov R; Krivtchik AA; Cinatl J; Kornhuber B; Cinatl J
    Folia Biol (Praha); 1999; 45(5):185-91. PubMed ID: 10730887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
    Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
    Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of antiepileptic drugs on immune system].
    Basta-Kaim A; Budziszewska B; LasoĊ„ W
    Przegl Lek; 2008; 65(11):799-802. PubMed ID: 19205364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immune system--is it relevant to cancer development, progression and treatment?
    Prestwich RJ; Errington F; Hatfield P; Merrick AE; Ilett EJ; Selby PJ; Melcher AA
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):101-12. PubMed ID: 18037277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells.
    Zhu Q; Liu JY; Yang CM; Xu HW; Zhang AZ; Cui Y; Wang HB; Qin CY; Li YQ
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1071-7. PubMed ID: 16957513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy.
    Dou QP; Smith DM; Daniel KG; Kazi A
    Prog Cell Cycle Res; 2003; 5():441-6. PubMed ID: 14593738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metal-based antitumour drugs in the post genomic era.
    Dyson PJ; Sava G
    Dalton Trans; 2006 Apr; (16):1929-33. PubMed ID: 16609762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunologic approaches to ovarian cancer treatment.
    Sabbatini P; Odunsi K
    J Clin Oncol; 2007 Jul; 25(20):2884-93. PubMed ID: 17617519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovarian tumour antigens as potential targets for immune gene therapy.
    Kuiper M; Peakman M; Farzaneh F
    Gene Ther; 1995 Jan; 2(1):7-15. PubMed ID: 7712335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes.
    Markasz L; Skribek H; Uhlin M; Otvos R; Flaberg E; Eksborg S; Olah E; Stuber G; Szekely L
    J Immunother; 2008 Apr; 31(3):283-93. PubMed ID: 18317359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Making sense of cancer chemotherapy.
    Holmes S
    Nurs Times; 1996 Sep 4-10; 92(36):42-3. PubMed ID: 8868768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin 21: combination strategies for cancer therapy.
    Skak K; Kragh M; Hausman D; Smyth MJ; Sivakumar PV
    Nat Rev Drug Discov; 2008 Mar; 7(3):231-40. PubMed ID: 18259184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nucleologram variations in circulating lymphocytes after chemotherapy.
    Malacarne P; Marzola M; Santini A; Nielsen I
    Folia Biol (Praha); 1986; 32(5):349-53. PubMed ID: 3506525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biological effects of anthraquinones. II. Mutagenic, cancerogenic and antineoplastic effects. Effect on the immune system].
    Hrones I
    Cesk Farm; 1992 Jun; 41(3):108-11. PubMed ID: 1525850
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.